Related by context. All words. (Click for frequent words.) 70 registrational trial 68 randomized Phase 2b 67 randomized controlled Phase 67 Phase 1a clinical 67 ELACYT 67 LUX Lung 67 GOUT 67 multicenter Phase 67 Phase Ib clinical 67 Phase IIIb clinical 67 axitinib 66 Initiate Phase 66 PEG IFN 66 mCRC patients 66 phase IIb clinical 66 Randomized Phase 66 ongoing Phase 1b 66 glufosfamide 66 oral ridaforolimus 66 APPRAISE 65 BCIRG 65 multicenter randomized controlled 65 assessing T DM1 65 Phase Ib II 65 fosbretabulin 65 placebo controlled Phase 65 EOquin TM 65 dose escalation clinical 65 prospectively defined 65 IL# PE#QQR 65 randomized Phase III 65 Phase Ib study 65 phase IIa 65 ABCSG 65 vidofludimus 65 Phase III randomized controlled 65 NSABP B 65 HuMax EGFr 65 phase Ib 65 dose cohort 64 EURIDIS 64 CIMZIA TM certolizumab pegol 64 Doxil ® 64 BRIM3 64 Cloretazine ® 64 SPIRIT FIRST 64 phase IIb 64 phase IIa clinical 64 multicenter phase 64 CLL SLL 64 CALGB # [002] 64 Pivotal Phase III 64 Phase #b/#a clinical 64 AVADO 64 phase IIIb 64 recurrent glioblastoma multiforme 64 ZACTIMA 64 randomized Phase IIb 64 antibody MAb 64 huN# DM1 64 multicenter randomized placebo controlled 64 SNT-MC#/idebenone 64 Phase 2a clinical 63 Pivotal Phase 63 depsipeptide 63 CLARITY study 63 VELCADE melphalan 63 GAMMAGARD 63 SUCCEED trial 63 Phase 1b clinical 63 ruxolitinib 63 lymphoid malignancies 63 COPERNICUS 63 IV NSCLC 63 Bezielle 63 INCB# [001] 63 TLK# 63 Allovectin 7 63 UPLYSO 63 Metastatic Melanoma 63 multicentre randomized 63 crizotinib PF # 63 mRCC 63 dosing cohort 63 sunitinib Sutent 63 MEND CABG II 63 PFO migraine 63 inhibitor RG# 63 Phase IIB 63 phase IIb study 63 BR.# 63 ECOG 63 dose escalation Phase 63 multiple myeloma MM 63 Phase IIb trials 63 ara C 62 Initiated Phase 62 CALGB 62 viral kinetics 62 omacetaxine mepesuccinate 62 placebo controlled clinical 62 Amrubicin 62 phase IIb III 62 Phase 2b Clinical Trial 62 sorafenib Nexavar 62 metastatic castration resistant 62 davunetide intranasal AL 62 recurrent glioblastoma 62 Zybrestat 62 prostate cancer mCRPC 62 VNP#M 62 oblimersen 62 pharmacokinetics PK 62 elacytarabine 62 Hodgkin lymphoma HL 62 Phase III psoriasis 62 nab paclitaxel 62 Genasense ® 62 EORTC 62 Phase 1a 62 huC# DM4 62 recurrent GBM 62 pralatrexate injection 62 unresectable stage 62 ZYBRESTAT TM 62 TRANSFORMS 62 Aflibercept 62 Pharmacokinetics PK 62 pharmacokinetic PK study 62 cancer mCRC 62 Tarceva TM 62 adecatumumab 62 Phase IIa clinical 62 mg kg BID 62 relapsed refractory multiple myeloma 62 nonmetastatic 62 pharmacokinetic PK 62 phase 2a 62 liposomal amphotericin B 62 gemcitabine carboplatin 62 MabCampath 62 cinacalcet 62 metastatic renal cell carcinoma 62 ORENCIA ® 62 brivaracetam 62 TASKi2 62 XL# SAR# 62 mg/m2 dose 62 bendamustine 62 HCV SPRINT 62 ExTRACT TIMI 62 photoprotective drug 62 Pivotal Trial 62 ENDEAVOR III 62 generation purine nucleoside 62 Pharmacokinetic 62 Pemetrexed 62 temsirolimus 61 refractory chronic lymphocytic 61 NEVO RES 61 Phase Ia 61 evaluating tivozanib 61 NSABP 61 Phase IIB clinical 61 lintuzumab 61 estramustine 61 metastatic CRC 61 plus prednisone 61 preclinical efficacy 61 PERSEUS 61 randomized multicenter Phase III 61 TAXUS ATLAS 61 forodesine 61 pain palliation 61 TRO# 61 Telintra 61 viral kinetic 61 PRE SURGE 61 HGS ETR2 61 Phase 2a trial 61 pharmacodynamic PD 61 Phase 2b kidney transplant 61 EndoTAG TM -1 61 BRIM2 61 metastatic malignant 61 neratinib 61 Myelodysplastic Syndrome MDS 61 IMA# 61 tanespimycin 61 Phase IIb clinical 61 Ophena TM 61 Vitaxin 61 NO# [002] 61 metastatic pancreatic 61 Phase Ib 61 recurrent NSCLC 61 standard chemotherapy regimen 61 Cloretazine R VNP#M 61 RE SURGE 61 Pegasys plus Copegus 61 Ozarelix 61 Cloretazine 61 iniparib 61 Quinamed 61 MIVI III 61 ToGA 61 5-fluorouracil/leucovorin 61 PRECISE trial 61 placebo controlled Phase III 61 entinostat 61 HSCT 61 Xelox 61 placebo controlled randomized 61 STRIDE PD 61 plus gemcitabine 61 resected pancreatic cancer 61 ErbB2 positive 61 pomalidomide 61 leukemia AML 61 Free Survival PFS 60 docetaxel chemotherapy 60 ascending dose 60 Parathyroid Hormone 60 aflibercept 60 ABSORB trial 60 Prednisone Against Refractory 60 RADIANT 60 Trial Evaluating 60 stage IIIB 60 dose melphalan 60 CA9 SCAN 60 Aplidin 60 elotuzumab 60 HDAC Inhibitor 60 pediatric acute lymphoblastic 60 pegylated liposomal doxorubicin 60 alvespimycin 60 fluorouracil leucovorin 60 relapsing multiple sclerosis 60 afatinib 60 CLL8 60 relapsed MM 60 Xanafide 60 multicenter Phase II 60 ORMD 60 IMPACT IMmunotherapy 60 HER2 positive metastatic breast 60 treatment naive genotype 60 sunitinib malate 60 docetaxel Taxotere ® 60 lintuzumab SGN 60 randomized Phase 60 refractory acute myeloid 60 patients evaluable 60 Tanespimycin 60 zalutumumab 60 adecatumumab MT# 60 chemoradiotherapy 60 doxorubicin docetaxel 60 Safinamide 60 trastuzumab DM1 60 Dacogen injection 60 TMC# C# 60 Phase 2b clinical 60 RE LY ® 60 IFN α 60 anti leukemic 60 darinaparsin ZIO 60 ZYBRESTAT 60 rALLy trial 60 bevacizumab Avastin ® 60 Cell Lymphoma 60 Phase IIb clinical trials 60 Plicera 60 ISTODAX ® 60 phase IIb trial 60 BrachySil TM 60 MGd 60 Phase 2b study 60 Phase III HEAT 60 randomized multicenter trial 60 radiation sensitizer 60 fluoropyrimidine 60 multicenter prospective 60 MAGE A3 60 SABCS 60 demonstrated antitumor activity 60 adjuvant tamoxifen 60 II Clinical Trial 60 metastatic HRPC 60 Ceflatonin 60 metastatic castrate resistant 60 EFAPROXYN 60 neoadjuvant 60 orBec 60 phase Ib clinical 60 MAGE A3 ASCI 60 Phase III VISTA 60 lumiliximab 60 complete cytogenetic response 60 Phase #b/#a 60 CTAP# Capsules 60 TASKi3 60 MORAb 60 initiated Phase Ib 60 #nd EORTC NCI 60 Severe Sepsis 60 plus dexamethasone 60 Telcyta 60 KRAS wild 60 pertuzumab 60 cetuximab Erbitux 60 LUMINATE 60 Zenvia Phase III 60 Panzem R NCD 60 PROSTVAC TM 60 SVR# 60 Phase III randomized 60 interferon gamma 1b 60 Clinical Trial Results 60 QD dosing 60 metastatic renal cell 60 adjuvant cisplatin 60 mcg dose 60 PROSTVAC VF 60 HCV RESPOND 2 60 HORIZONS AMI trial 60 zanolimumab 60 Phase III pivotal 59 PSMA ADC 59 #mg/m# [002] 59 riociguat 59 farletuzumab 59 EDEMA4 59 ROCKET AF 59 CIMZIA TM 59 multicenter placebo controlled 59 Copegus ribavirin 59 LCP Tacro 59 KRAS status 59 Denufosol 59 PXD# 59 NOX E# 59 Onconase 59 pT2 59 AEGR 59 PRECiSE 59 IMGN# 59 RSR# 59 galiximab 59 cetuximab Erbitux R 59 ILLUMINATE 59 tocilizumab 59 pan HDAC inhibitor 59 dose escalation trial 59 TORISEL 59 Alocrest 59 stage IIIb IV 59 Trovax 59 Multiple Myeloma MM 59 Androxal TM 59 Phase 2b monotherapy 59 Apoptone 59 OVATURE 59 Nexavar sorafenib 59 metastatic hormone refractory 59 CLIRS 59 Azacitidine 59 PEG SN# 59 prucalopride 59 HoFH 59 fidaxomicin Phase 59 TELCYTA 59 subgroup analyzes 59 refractory AML 59 melphalan prednisone 59 CUSTOM III 59 progression TTP 59 ancrod 59 CA4P 59 Phase 1b clinical trials 59 FORTIS M trial 59 ADAGIO study 59 TTF Therapy 59 Phase 1b trial 59 hA# 59 novel histone deacetylase 59 allogeneic hematopoietic stem cell 59 Multiple Ascending Dose 59 Meets Primary Endpoint 59 PEGylated interferon beta 1a 59 neurologic progression 59 Phase 1b 59 Targretin 59 Phenoptin 59 severe oral mucositis 59 Phase III Trial 59 receptor tyrosine kinase inhibitor 59 trodusquemine 59 recurrent metastatic 59 Flu Cy 59 romidepsin novel 59 TOLAMBA 59 TroVax ® 59 velafermin 59 Efficacy Results 59 trastuzumab DM1 T DM1 59 FOLFOX4 59 AIR2 Trial 59 M Vax 59 Hazard Ratio 59 ribavirin Copegus ® 59 liposomal doxorubicin 59 CEQ# 59 Cimzia ® certolizumab pegol 59 DermaVir Patch 59 Pegylated Liposomal Doxorubicin 59 IIIA NSCLC 59 systemic ALCL 59 Randomised 59 stage IIIb 59 sipuleucel T 59 biliary tract cancer 59 Brentuximab Vedotin SGN 59 investigational antiplatelet agent 59 APEX PD 59 Pivotal Study 59 TG MV 59 subanalysis 59 Nuvion 59 Metastatic Colorectal Cancer 59 plus COPEGUS 59 HIF PHI 59 TG# [001] 59 histologically confirmed 59 Adjuvant Treatment 59 Successfully Completes Phase 59 custirsen 59 Placebo Controlled Trial 59 evaluable subjects 59 Vascular Disrupting Agent 59 Fast Tracked Phase 59 ENDEAVOR II 59 hepatocellular carcinoma HCC 59 biochemical relapse 59 PSN# [002] 59 CHAMPION PCI 59 evaluable patients 59 registrational 59 PROVENGE sipuleucel T 59 ISEL 59 evaluating REVLIMID 59 HGS ETR1 59 Cutaneous T 59 efficacy endpoint 59 PANVAC VF 59 Relapsed Refractory 59 Study Evaluating 59 Phase IIb III 59 INC# 59 beta 1a 59 RE LY 59 teriflunomide 59 unresectable 59 NovoTTF 59 Virulizin ® 59 ganetespib 59 ritonavir boosted 59 double blinded randomized 59 BARACLUDE ® 59 TMC# [002] 59 Prospective Randomized 59 ritonavir boosted danoprevir 59 Phase IIa trial 59 DASISION 59 Sorafenib HCC Assessment 59 MEND CABG 59 R#/MEM # 59 RhuDex ® 59 Phase 2b Study 59 stated Michelle Berrey 59 Allovectin 7 R 59 Phase 2b trial 59 EndoTAGTM 1 59 cetuximab Erbitux ® 59 TKM ApoB 59 debulking surgery 58 mg kg dose 58 everolimus eluting stents 58 Azedra 58 talactoferrin 58 EDEMA3 58 Allovectin 7 ® 58 HER2 antibody 58 undetectable HBV DNA 58 Clolar ® 58 Phase #b/#a trial 58 histone deacetylase HDAC inhibitor 58 ribavirin RBV 58 neoadjuvant treatment 58 liposomal formulation 58 genotypic resistance 58 prostate cancer AIPC 58 FOLFOX 58 oral prodrug 58 Phase III ALLEGRO 58 Panzem NCD 58 Interferon Alfa 58 Dacogen decitabine 58 comparator arm 58 trabectedin 58 metastatic GIST 58 inhaled AAT 58 Pharmacokinetic PK 58 Onrigin 58 dose dexamethasone 58 3 registrational trial 58 locoregional disease 58 Natalizumab 58 tarenflurbil 58 ISAR TEST 58 briakinumab 58 PEGylated Fab fragment 58 antitumor activity 58 Breast Cancer Assay 58 confirmatory Phase III 58 evaluable 58 Acute Ischemic Stroke 58 RIBBON 58 CRMD# 58 MERLIN TIMI 58 YERVOY 58 Phase Ib IIa 58 null responder 58 mapatumumab 58 decitabine 58 Oral Fingolimod 58 azacitidine 58 controlled multicenter Phase 58 Subgroup analysis 58 heavily pretreated 58 INCB# [003] 58 Prosaptide 58 AVONEX ® 58 concurrent chemoradiation 58 Temsirolimus 58 CBLC# 58 ixabepilone 58 Hormone Refractory Prostate Cancer 58 bortezomib Velcade 58 RECIST Response Evaluation Criteria 58 AP# [003] 58 Forodesine HCl 58 Phase 2a Study 58 BRAF inhibitor 58 Kaplan Meier analysis 58 randomized multicentre 58 advanced hepatocellular carcinoma 58 CR# vcMMAE 58 recurrent GBM patients 58 IV melanoma 58 paclitaxel carboplatin 58 Glufosfamide 58 PROSTVAC ® 58 Patients Treated With 58 gemcitabine Gemzar ® 58 Phase IIIb 58 evaluating Actimmune 58 leukemia ALL 58 FOLOTYN ® 58 chemoradiation therapy 58 resminostat 58 heavily pretreated patients 58 Vidaza azacitidine 58 initiate Phase 1b 58 eribulin mesylate 58 low dose cytarabine 58 romidepsin 58 thymalfasin 58 prospective multicenter 58 NLX P# 58 Randomized Phase II 58 RECORD1 58 Folfox 58 fluvastatin 58 teduglutide 58 EGS# 58 prostate cancer CRPC 58 IV malignant melanoma 58 Irinotecan 58 Initiate Clinical Trial 58 peg interferon 58 hoFH 58 oral Hycamtin 58 CoFactor 58 BCR ABL inhibitor 58 CINTREDEKIN BESUDOTOX 58 visceral metastases 58 tumors GIST 58 HBeAg 58 IRX 2 58 Median PFS 58 Platinol ® 58 ofatumumab HuMax CD# 58 cilengitide 58 Hsp# Inhibitor 58 BEACOPP 58 ANCHOR trial 58 catheter occlusion 58 masked placebo controlled 58 mTOR inhibitor 58 Controlled Trial 58 oral COTI 58 oral Xeloda 58 pharmacokinetic PK profile 58 Neoadjuvant 58 vandetanib 58 fallopian tube carcinoma 58 Omacetaxine 58 PKC# 58 varespladib 58 Phase 2b 58 metastatic RCC 58 PRTX 58 Phase #/#a 58 refractory colorectal cancer 58 efaproxiral 58 8mg/kg 58 epoetin alpha 58 Chronic Lymphocytic Leukemia 58 EGFR TKI 58 Relapsing Multiple Sclerosis 58 Aclidinium 58 CORD II 58 prospective multicenter randomized 58 EVEREST II 58 KRAS mutations occur 58 Phase Ib Clinical Trial 58 novel VDA molecule 58 VESTASYNC 58 Median progression 58 seliciclib CYC# 58 tremelimumab 58 Romidepsin 58 Azixa 58 CLORETAZINE TM VNP#M 58 monoclonal antibody conjugated 58 noninferiority 58 GetGoal Phase III 58 L MTP PE 58 rALLy 58 ACTEMRA TM 58 Phase IIb Clinical Trial 58 FOLFOX6 58 RTOG 58 ASSERT 58 gemcitabine cisplatin 58 deforolimus 58 velafermin belinostat 58 Daclizumab 58 sulodexide 58 multikinase inhibitor 58 peginesatide 58 orally inhaled migraine 58 Femara letrozole 58 adjuvant radiation 58 NEVO ™ 58 non splenectomized 58 pancreatic islet cell 58 cell lymphoma CTCL 58 imatinib therapy 58 denileukin diftitox 58 Kamada AAT 58 alpha 2a 58 OvaRex ® MAb 58 ECASS 58 Enzastaurin 58 docetaxel Taxotere 58 CANCIDAS 58 Gynecologic Oncology Group 58 abiraterone acetate 57 Neo Bladder Augment 57 previously untreated follicular 57 virological response 57 PRT# 57 urocortin 2 57 ThermoDox R 57 Phase Ib IIa clinical 57 pegylated interferon alpha 57 refractory CLL 57 Pimavanserin 57 somatostatin analogue 57 relapsed multiple myeloma 57 IRESSA 57 CombAT 57 interferon alfa 57 Sym# 57 BiTE antibody MT# 57 HRPC 57 R# #mg BID 57 completely resected 57 ponatinib 57 PRECISE 57 PreCISe 57 multicenter randomized 57 Preclinical Study 57 Taxotere ® 57 HCV Genotype 57 ADXS# 57 QLT# 57 dose cohorts 57 Phase III Clinical Trial 57 dextromethorphan quinidine 57 hepatocellular cancer 57 Dose Ranging Study 57 solithromycin 57 AVASTIN 57 Long Term Efficacy 57 CAMMS# 57 Vascugel ® 57 cytokine refractory 57 OvaRex R 57 Pralatrexate 57 rALLy clinical trial 57 Vandetanib 57 KNS # 57 CDK inhibitor 57 mg/m2 cohort 57 dasatinib Sprycel ® 57 Proxinium TM 57 surrogate endpoint 57 TO AVOID PREGNANCY WHILE 57 ATL# [001] 57 PREVENT IV 57 palifermin 57 dacetuzumab 57 confirmatory clinical 57 L BLP# 57 CRLX# 57 Stage IIIb 57 RhuDex R 57 sunitinib 57 rapid virologic response 57 HCV genotype 57 AEG# 57 icatibant 57 virus HCV protease inhibitor 57 multicenter Phase III 57 oral deforolimus 57 intratumoural 57 MADIT 57 YONDELIS 57 Chronic Hepatitis C 57 maribavir 57 MADIT II 57 Completes Patient Enrollment 57 sodium thiosulfate STS 57 taxane resistant 57 ChronVac C ® 57 ularitide 57 TroVax 57 locoregional recurrence 57 HuMax CD# 57 Follicular Lymphoma 57 initiate Phase 2b 57 Pegylated Interferon 57 evaluating Prochymal 57 BrachySil ™ 57 mCRC 57 randomized discontinuation trial 57 SWOG 57 Diffuse Large B 57 neoadjuvant chemotherapy 57 Phase IIIb study 57 Pharmacodynamic 57 preclinical pharmacokinetic 57 5 Fluorouracil 57 peginterferon alfa 2a #KD 57 taxane refractory 57 Ranolazine 57 alemtuzumab Campath 57 lorvotuzumab mertansine 57 JAK2 inhibitor 57 dose escalation phase 57 Panzem R 57 colon carcinoma 57 CRp 57 Ocrelizumab 57 lanthanum carbonate 57 Afatinib 57 Idiopathic Pulmonary Fibrosis 57 disease progression TTP 57 ataluren 57 pegylated interferon alfa 2b 57 ARDIS 57 FOLFIRI 57 zotarolimus eluting stent 57 HBeAg negative patients 57 dexanabinol 57 randomized multicenter 57 HGPIN 57 humanized interleukin 6 57 budesonide foam 57 SAR# [004] 57 BIBW 57 median PFS 57 Monotherapy 57 CYT# 57 adenoma recurrence 57 Adenoma Prevention 57 ATAC Arimidex Tamoxifen Alone 57 Vectibix panitumumab 57 Genasense ® oblimersen 57 dacarbazine DTIC 57 ADVEXIN clinical 57 Stage IIB 57 CIMZIA ™ 57 Glypromate 57 vascular disrupting agent 57 q#h 57 orally bioavailable 57 Phase Ib clinical trials 57 RG# [001] 57 IIa trial 57 mg qd 57 underwent resection 57 Valortim R 57 colesevelam HCl 57 ENDEAVOR IV 57 Prolongs Survival 57 severe neutropenia 57 HeFH 57 CD3 monoclonal antibody 57 Zemplar Capsules 57 dacarbazine 57 systemically administered 57 induced macular edema 57 Mantle Cell Lymphoma 57 Phase III ThermoDox 57 DAPT 57 VIR# 57 VcMP 57 Stent Restenosis 57 MVA MUC1 IL2 57 Taxotere chemotherapy 57 Aptivus ® 57 ON #.Na 57 Decitabine 57 Secondary endpoints 57 tipranavir r 57 Intravitreal 57 GW# [003] 57 CVac 57 refractory metastatic colorectal cancer 57 IMPACT DCM 57 OvaRex 57 GVAX R 57 Initiates Phase 57 Teysuno 57 enzastaurin 57 mitoxantrone plus 57 HDL Selective Delipidation 57 pharmacokinetic parameters 57 BOLDER II 57 calcineurin inhibitor 57 genotype 1a 57 Intervention Effectiveness 57 oral FTY# 57 ENESTnd 57 bosentan 57 ADVANCE PD 57 Peginterferon 57 oxymorphone ER 57 EOquin 57 untreated multiple myeloma 57 SNT MC# 57 Troxatyl 57 Immunotherapeutic 57 locoregional 57 TASQ 57 Advaxis Phase 57 EchoCRT 57 prostate cancer HRPC 57 sustained virological response 57 HBeAg positive patients 57 Zarnestra 57 rindopepimut 57 Prostate AdenoCarcinoma Treatment 57 registrational clinical 57 PF # [002] 57 platinum refractory 57 RezularTM 57 seliciclib 57 OPAXIO 57 canakinumab 57 OvaRex MAb 57 docetaxel Taxotere R 57 #mg dosing group 57 irreversible inhibitor 57 Combination REOLYSIN R 57 ORAL Sync 57 Multicenter 57 TAXUS V 57 pivotal Phase 57 trabedersen 57 LBH# 57 ELIQUIS 57 Neulasta ® 57 ZYBRESTAT fosbretabulin 57 Gemzar ® 57 Torisel 57 GVAX 57 SIR Spheres 57 Cethromycin 57 bevacizumab Avastin 57 PF # [001] 57 Cimzia TM 57 polycythemia vera essential thrombocythemia 57 Personalized Immunotherapy 57 SYMMETRY trial 57 Diabetic Macular Edema DME 57 Engerix B 57 Triapine R 57 Tavocept 57 #mg dose [002] 56 mildly symptomatic 56 gefitinib Iressa 56 erlotinib Tarceva ® 56 bosutinib 56 Solid Tumors 56 NEUVENGE 56 posaconazole 56 selective modulator 56 amrubicin 56 LHRH receptor positive 56 peginterferon alpha 2a 56 investigational protease inhibitor 56 ruboxistaurin 56 Phase IIa trials 56 omega interferon 56 Halaven 56 statistically significant p = 56 cisplatin vinorelbine 56 relapsed refractory 56 PROVENGE ® 56 OXi# 56 Sprycel dasatinib 56 Antiviral Activity 56 systemic anaplastic large 56 CHARM Added 56 fidaxomicin Phase 3 56 prospective randomized controlled 56 prospective randomized placebo 56 Factor VIIa 56 thalidomide Thalomid 56 GV# [001] 56 relapsed ALL 56 CR CRu 56 CR nPR 56 Demonstrates Significant 56 Phase III confirmatory 56 targeting CD# 56 TH# [003] 56 Cloretazine R 56 octreotide implant 56 abacavir lamivudine 56 Aurexis 56 eluting stent 56 Presents Preclinical Data 56 KRN# 56 fallopian tube cancers 56 receptor blocker 56 certolizumab 56 chlorambucil 56 dosing cohorts 56 nonclinical studies 56 HepaSphere 56 APOPTONE 56 PD LID 56 grade cervical intraepithelial 56 Bortezomib 56 HuMax CD4 56 CCX# B 56 Response Evaluation Criteria 56 Seliciclib 56 NCT# ClinicalTrials.gov 56 myeloid metaplasia 56 DCVax ® Brain 56 Epratuzumab 56 ASA# 56 Glybera 56 CLARITY TIMI 56 trial evaluating PRX# 56 aurora kinase 56 RhuDex TM 56 Sipuleucel T 56 registrational Phase 56 mucosal healing 56 AZILECT R